Australian Doctors Frequently Prescribe High-THC Medicinal Cannabis, Review Finds
A recent review indicates that Australian doctors are frequently prescribing medicinal cannabis products with significantly higher concentrations of THC than those used in clinical trials. Researchers from Monash University examined the available evidence concerning the efficacy and safety of these high-potency THC products, which are currently being prescribed across Australia. THC, or delta-9-tetrahydrocannabinol, is identified as the primary psychoactive component of cannabis. The review highlighted that out of over 1,000 medicinal cannabis products available on the market, only a small fraction, specifically two products, have undergone evaluation by the Therapeutic Goods Administration (TGA), Australia's drug regulator. This suggests a potential gap in regulatory oversight for many of the products patients are receiving.
The widespread prescription of medicinal cannabis with THC concentrations exceeding those in clinical trials raises questions about the alignment between therapeutic use and regulatory assessment in Australia. While high-THC products may offer symptomatic relief, the limited TGA evaluation of available products suggests potential risks related to dosage control and long-term safety profiles. This situation underscores the need for robust pharmacovigilance and clear guidelines to ensure patient safety and therapeutic efficacy in a rapidly evolving market. Future considerations should focus on harmonizing product availability with evidence-based clinical practice and regulatory standards to mitigate potential adverse outcomes and build patient and clinician confidence.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.